ObsEva is a Swiss-based company dedicated to the development of innovative drugs for women’s reproductive medicine. ObsEva’s main focus is on therapies for preterm labor. ObsEva´s lead product is a clinical stage compound licensed from Merck Serono.


Team Member
more about
Jasper Bos
Latest News Entry
ObsEva Announces Presentations Related to its Assisted Reproductive Technology (ART) and Pre-term labor (PTL) Development Programs at ESHRE 2017 Annual Meeting
  • Phase 2 nolasiban previously reported data supports potential for meaningfully increasing live birth rates in ART
  • Non-clinical results of OBE022 for PTL demonstrate both monotherapy/combination potential
all portfolio news